MX393608B - Profilactico o agente terapeutico para queratitis fungica. - Google Patents

Profilactico o agente terapeutico para queratitis fungica.

Info

Publication number
MX393608B
MX393608B MX2018003381A MX2018003381A MX393608B MX 393608 B MX393608 B MX 393608B MX 2018003381 A MX2018003381 A MX 2018003381A MX 2018003381 A MX2018003381 A MX 2018003381A MX 393608 B MX393608 B MX 393608B
Authority
MX
Mexico
Prior art keywords
prophylactic
therapeutic agent
fungal keratitis
keratitis
fungal
Prior art date
Application number
MX2018003381A
Other languages
English (en)
Spanish (es)
Other versions
MX2018003381A (es
Inventor
Jinzhong Zhang
Masaaki Kageyama
Original Assignee
Santen Pharmaceutical Co Ltd
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Santen Pharmaceutical Co Ltd filed Critical Santen Pharmaceutical Co Ltd
Publication of MX2018003381A publication Critical patent/MX2018003381A/es
Publication of MX393608B publication Critical patent/MX393608B/es

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/4353—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom ortho- or peri-condensed with heterocyclic ring systems
    • A61K31/436—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom ortho- or peri-condensed with heterocyclic ring systems the heterocyclic ring system containing a six-membered ring having oxygen as a ring hetero atom, e.g. rapamycin
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/06—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite
    • A61K47/08—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite containing oxygen, e.g. ethers, acetals, ketones, quinones, aldehydes, peroxides
    • A61K47/10—Alcohols; Phenols; Salts thereof, e.g. glycerol; Polyethylene glycols [PEG]; Poloxamers; PEG/POE alkyl ethers
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/30—Macromolecular organic or inorganic compounds, e.g. inorganic polyphosphates
    • A61K47/34—Macromolecular compounds obtained otherwise than by reactions only involving carbon-to-carbon unsaturated bonds, e.g. polyesters, polyamino acids, polysiloxanes, polyphosphazines, copolymers of polyalkylene glycol or poloxamers
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/0012—Galenical forms characterised by the site of application
    • A61K9/0019—Injectable compositions; Intramuscular, intravenous, arterial, subcutaneous administration; Compositions to be administered through the skin in an invasive manner
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/0012—Galenical forms characterised by the site of application
    • A61K9/0048—Eye, e.g. artificial tears
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P27/00—Drugs for disorders of the senses
    • A61P27/02—Ophthalmic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/10—Antimycotics

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Medicinal Chemistry (AREA)
  • Animal Behavior & Ethology (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Epidemiology (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Ophthalmology & Optometry (AREA)
  • Organic Chemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Oil, Petroleum & Natural Gas (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Inorganic Chemistry (AREA)
  • Oncology (AREA)
  • Communicable Diseases (AREA)
  • Dermatology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Medicinal Preparation (AREA)
  • Nitrogen And Oxygen Or Sulfur-Condensed Heterocyclic Ring Systems (AREA)
MX2018003381A 2015-09-18 2016-09-13 Profilactico o agente terapeutico para queratitis fungica. MX393608B (es)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US201562220847P 2015-09-18 2015-09-18
PCT/JP2016/077014 WO2017047597A1 (ja) 2015-09-18 2016-09-13 角膜真菌症の予防または治療剤

Publications (2)

Publication Number Publication Date
MX2018003381A MX2018003381A (es) 2018-08-15
MX393608B true MX393608B (es) 2025-03-24

Family

ID=58288799

Family Applications (1)

Application Number Title Priority Date Filing Date
MX2018003381A MX393608B (es) 2015-09-18 2016-09-13 Profilactico o agente terapeutico para queratitis fungica.

Country Status (13)

Country Link
US (1) US10166217B2 (cg-RX-API-DMAC7.html)
EP (1) EP3351244A4 (cg-RX-API-DMAC7.html)
JP (1) JP6639364B2 (cg-RX-API-DMAC7.html)
KR (1) KR20180053340A (cg-RX-API-DMAC7.html)
CN (1) CN108025000A (cg-RX-API-DMAC7.html)
BR (1) BR112018005305A2 (cg-RX-API-DMAC7.html)
HK (2) HK1256969A1 (cg-RX-API-DMAC7.html)
MX (1) MX393608B (cg-RX-API-DMAC7.html)
MY (1) MY183906A (cg-RX-API-DMAC7.html)
PH (1) PH12018500579A1 (cg-RX-API-DMAC7.html)
SG (1) SG11201802091RA (cg-RX-API-DMAC7.html)
TW (1) TWI721015B (cg-RX-API-DMAC7.html)
WO (1) WO2017047597A1 (cg-RX-API-DMAC7.html)

Families Citing this family (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CN112957321B (zh) * 2021-03-04 2022-08-05 青岛大学附属医院 一种氧化硫酸软骨素改性的那他霉素滴眼液及其制备方法
CN114568490B (zh) * 2022-04-01 2023-12-19 眉山职业技术学院(眉山技师学院) 雷帕霉素在抑制柑橘青霉菌生长中的应用

Family Cites Families (4)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CN101137369A (zh) * 2005-02-09 2008-03-05 马库赛特公司 用于眼治疗的制剂
CA2597590A1 (en) 2005-02-09 2006-08-17 Macusight, Inc. Formulations for ocular treatment
AU2007230964B2 (en) 2006-03-23 2012-07-19 Santen Pharmaceutical Co., Ltd. Formulations and methods for vascular permeability-related diseases or conditions
EP2187743B1 (en) * 2007-08-16 2014-07-30 Santen Pharmaceutical Co., Ltd Rapamycin formulations for treatment of age related macular degeneration

Also Published As

Publication number Publication date
BR112018005305A2 (pt) 2018-10-09
HK1253545A1 (zh) 2019-06-21
EP3351244A1 (en) 2018-07-25
JP2017057199A (ja) 2017-03-23
KR20180053340A (ko) 2018-05-21
MY183906A (en) 2021-03-17
WO2017047597A1 (ja) 2017-03-23
EP3351244A4 (en) 2019-05-01
TWI721015B (zh) 2021-03-11
CN108025000A (zh) 2018-05-11
SG11201802091RA (en) 2018-04-27
US20180271841A1 (en) 2018-09-27
PH12018500579A1 (en) 2018-09-10
MX2018003381A (es) 2018-08-15
HK1256969A1 (en) 2019-10-04
US10166217B2 (en) 2019-01-01
TW201717943A (zh) 2017-06-01
JP6639364B2 (ja) 2020-02-05

Similar Documents

Publication Publication Date Title
DK3706796T3 (da) Eksosomerer som RNA terapeutikske midler
MX378273B (es) Compuestos activos hacia bromodominios.
MX386598B (es) Compuestos antibacterianos.
MX2016016593A (es) Nuevos derivados de aminoalquibenzotiazepina y usos de los mismos.
NZ742208A (en) Topical pharmaceutical formulations for treating inflammatory-related conditions
MX2016016666A (es) Derivados de acido boronico y usos terapeuticos de los mismos.
MX2016015093A (es) Derivados de acido boronico y sus usos terapeuticos.
CL2016001895A1 (es) Compuestos
MX2019014041A (es) Inhibidores pirazolicos de magl.
EA201790785A1 (ru) Производные тетрагидроизохинолина
PE20160052A1 (es) Composicion farmaceutica de clorhidrato de s-cetamina
EA201690513A1 (ru) Комбинация ингибитора mek и ингибитора erk для применения в лечении гиперпролиферативных заболеваний
MX374944B (es) Derivado de piranocromenil fenol, y composición farmacéutica para tratar un síndrome metabólico o enfermedad inflamatoria.
CL2015002897A1 (es) Inhibidores de bace1
MX2016013236A (es) Formulacion inmunosupresora.
BR112017000730B8 (pt) Derivados de pirrolidinona como inibidores de metap-2, e medicamentos
CO2017012645A2 (es) Agente antihipertensivo que comprende s-1-propenilcisteína o una sal del mismo como ingrediente activo
MX381792B (es) Agente terapéutico para la fibrosis.
EA201691741A1 (ru) Фармацевтическая композиция
MX383940B (es) Formulación farmacéutica que contiene tocol fosfato.
EA201890212A1 (ru) Новое применение сульфата декстрана
PH12018500579A1 (en) Fungal keratitis prophylactic or therapeutic agent
MX373177B (es) Métodos de tratamiento de disquinesia y trastornos relacionados.
EA201501130A1 (ru) Офтальмологическая фармацевтическая композиция
PH12019502145A1 (en) Agent for preventing myopia, treating myopia, and/or preventing myopia progression comprising tiotropium as active ingredient